Clinical Trial Update: BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating afatinib (BIBW 2992) with or without daily temozolomide in patients with recurrent malignant glioma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Afatinib (afatinib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Glioma | Phase 2 | Status: COMPLETED | Results posted: 2014-01-24